Abstract
Herpesviruses are a prominent cause of human viral disease, second only to the cold and influenza viruses. Most herpesvirus infections are mild or asymptomatic. However, when the virus invades the eye, a number of pathologies can develop and its associated sequelae have become a considerable source of ocular morbidity. The most common culprits of herpetic eye disease are the herpes simplex virus (HSV), varicella zoster virus (VZV), and cytomegalovirus (CMV). While primary infection can produce ocular disease, the most destructive manifestations tend to arise from recurrent infection. These recurrent infections can wreck devastating effects and lead to irreversible vision loss accompanied by a decreased quality of life, increased healthcare usage, and significant cost burden. Unfortunately, no method currently exists to eradicate herpesviruses from the body after infection. Treatment and management of herpes-related eye conditions continue to revolve around antiviral drugs, although corticosteroids, interferons, and other newer therapies may also be appropriate depending on the disease presentation. Ultimately, the advent of effective vaccines will be crucial to preventing herpesvirus diseases altogether and cutting the incidence of ocular complications.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Akhtar J, Shukla D. 2009. Viral entry mechanisms: cellular and viral mediators of herpes simplex virus entry. FEBS J, 276: 7228–7236.
Al-Dujaili L J, Clerkin P P, Clement C, McFerrin H E, Bhattacharjee P S, Varnell E D, Kaufman H E, Hill J M. 2011. Ocular herpes simplex virus: how are latency, reactivation, recurrent disease and therapy interrelated? Future Microbiol, 6: 877–907.
Anderson J R, Behrens C, Binswanger I A, and al. e 2013, posting date. HIV Web Study. http://depts.washington.edu/hivaids/oit/case7/discussion.html.
Arvin A M. 1996. Varicella-zoster virus. Clin Microbiol Rev, 9: 361–381.
Arvin A M. 2007. Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge University Press, Cambridge; New York, pp. 1262–1273.
Azwa A, Barton S E. 2009. Aspects of herpes simplex virus: a clinical review. J Fam Plann Reprod Health Care, 35: 237–242.
Barron B A, Gee L, Hauck W W, Kurinij N, Dawson C R, Jones D B, Wilhelmus K R, Kaufman H E, Sugar J, Hyndiuk R A, Laibson P R, Stulting R D, Asbell P A. 1994. Herpetic Eye Disease Study. A controlled trial of oral acyclovir for herpes simplex stromal keratitis. Ophthalmology, 101: 1871–1882.
Belshe R B, Leone P A, Bernstein D I, Wald A, Levin M J, Stapleton J T, Gorfinkel I, Morrow R L, Ewell M G, Stokes-Riner A, Dubin G, Heineman T C, Schulte J M, Deal C D, Herpevac Trial for Women. 2012. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med, 366: 34–43.
Bloom J N, Palestine A G. 1988. The diagnosis of cytomegalovirus retinitis. Ann Intern Med, 109: 963–969.
Bowen E F, Griffiths P D, Davey C C, Emery V C, Johnson M A. 1996. Lessons from the natural history of cytomegalovirus. AIDS, 10Suppl 1: S37–S41.
Bradley H, Markowitz L E, Gibson T, McQuillan G M. 2014. Seroprevalence of herpes simplex virus types 1 and 2—United States, 1999–2010. J Infect Dis, 209: 325–333.
Buxbaum S, Geers M, Gross G, Schofer H, Rabenau H F, Doerr H W. 2003. Epidemiology of herpes simplex virus types 1 and 2 in Germany: what has changed? Med Microbiol Immunol, 192: 177–181.
Caserta M T, Mock D J, Dewhurst S. 2001. Human herpesvirus 6. Clin Infect Dis, 33: 829–833.
Cobo L M, Foulks G N, Liesegang T, Lass J, Sutphin J E, Wilhelmus K, Jones D B, Chapman S, Segreti A C, King D H. 1986. Oral acyclovir in the treatment of acute herpes zoster ophthalmicus. Ophthalmology, 93: 763–770.
Coleman J L, Shukla D. 2013. Recent advances in vaccine development for herpes simplex virus types I and II. Hum Vaccin Immunother, 9: 729–735.
Colin J, Chastel C, Kaufman H E, Kissling G E. 1987. Combination therapy for dendritic keratitis with acyclovir and vidarabine. J Ocul Pharmacol, 3: 39–42.
Daibata M, Komatsu T, Taguchi H. 2000. Human herpesviruses in primary ocular lymphoma. Leuk Lymphoma, 37: 361–365.
Damato E G, Winnen C W. 2002. Cytomegalovirus infection: perinatal implications. J Obstet Gynecol Neonatal Nurs, 31: 86–92.
Darougar S, Wishart M S, Viswalingam N D. 1985. Epidemiological and clinical features of primary herpes simplex virus ocular infection. Br J Ophthalmol, 69: 2–6.
Dartt D A, Dana R, D’Amore p, Niederkorn J. 2011. Immunology, Inflammation and Diseases of the Eye. San Diego: Academic Press.
Farhatullah S, Kaza S, Athmanathan S, Garg P, Reddy S B, Sharma S. 2004. Diagnosis of herpes simplex virus-1 keratitis using Giemsa stain, immunofluorescence assay, and polymerase chain reaction assay on corneal scrapings. Br J Ophthalmol, 88: 142–144.
Farooq A V, Shukla D. 2012. Herpes simplex epithelial and stromal keratitis: an epidemiologic update. Surv Ophthalmol, 57: 448–462.
Farooq A V, Shah A, Shukla D. 2010. The role of herpesviruses in ocular infections. Virus Adaptation and Treatment, 2: 115–123.
Fulop T, Larbi A, Pawelec G. 2013. Human T cell aging and the impact of persistent viral infections. Front Immunol, 4: 271.
Gershon A A, Gershon M D. 2010. Perspectives on vaccines against varicella-zoster virus infections. Curr Top Microbiol Immunol, 342: 359–372.
Gilden D H, Dueland A N, Devlin M E, Mahalingam R, Cohrs R. 1992. Varicella-zoster virus reactivation without rash. J Infect Dis, 166 Suppl 1: S30–S34.
Gimenez F, Suryawanshi A, Rouse B T. 2013. Pathogenesis of herpes stromal keratitis—a focus on corneal neovascularization. Prog Retin Eye Res, 33: 1–9.
Green L K, Pavan-Langston D. 2006. Herpes simplex ocular inflammatory disease. Int Ophthalmol Clin, 46: 27–37.
Gross G, Schofer H, Wassilew S, Friese K, Timm A, Guthoff R, Pau H W, Malin J P, Wutzler P, Doerr H W. 2003. Herpes zoster guideline of the German Dermatology Society (DDG). J Clin Virol, 26: 277–289.
Guess S, Stone D U, Chodosh J. 2007. Evidence-based treatment of herpes simplex virus keratitis: a systematic review. Ocul Surf, 5: 240–250.
Hamrah P, Sahin A, Dastjerdi M H, Shahatit B M, Bayhan H A, Dana R, Pavan-Langston D. 2012. Cellular changes of the corneal epithelium and stroma in herpes simplex keratitis: an in vivo confocal microscopy study. Ophthalmology, 119: 1791–1797.
Hennis H L, Scott A A, Apple D J. 1989. Cytomegalovirus retinitis. Surv Ophthalmol, 34: 193–203.
Hori J. 2008. Mechanisms of immune privilege in the anterior segment of the eye: what we learn from corneal transplantation. J Ocul Biol Dis Infor, 1: 94–100.
Hung S O, Patterson A, Rees P J. 1984. Pharmacokinetics of oral acyclovir (Zovirax) in the eye. Br J Ophthalmol, 68: 192–195.
Hwang C W, Jr., Steigleman W A, Saucedo-Sanchez E, Tuli S S. 2013. Reactivation of herpes zoster keratitis in an adult after varicella zoster vaccination. Cornea, 32: 508–509.
Kahloun R, Attia S, Jelliti B, Attia A Z, Khochtali S, Yahia S B, Zaouali S, Khairallah M. 2014. Ocular involvement and visual outcome of herpes zoster ophthalmicus: review of 45 patients from Tunisia, North Africa. J Ophthalmic Inflamm Infect, 4: 25.
Karsten E, Watson S L, Foster L J. 2012. Diversity of microbial species implicated in keratitis: a review. Open Ophthalmol J, 6: 110–124.
Kaufman H E. 1962. Clinical cure of herpes simplex keratitis by 5-iodo-2-deoxyuridine. Proc Soc Exp Biol Med, 109: 251–252.
Keating G M. 2013. Shingles (herpes zoster) vaccine (zostavax(®)): a review of its use in the prevention of herpes zoster and postherpetic neuralgia in adults aged ≥50 years. Drugs, 73: 1227–1244.
Kim S R, Khan F, Ramirez-Fort M K, Downing C, Tyring S K. 2014. Varicella zoster: an update on current treatment options and future perspectives. Expert Opin Pharmacother, 15: 61–71.
Knickelbein J E, Hendricks R L, Charukamnoetkanok P. 2009. Management of herpes simplex virus stromal keratitis: an evidence-based review. Surv Ophthalmol, 54: 226–234.
Kwong A D, Frenkel N. 1987. Herpes simplex virus-infected cells contain a function(s) that destabilizes both host and viral mRNAs. Proc Natl Acad Sci USA, 84: 1926–1930.
Labetoulle M, Auquier P, Conrad H, Crochard A, Daniloski M, Bouee S, El Hasnaoui A, Colin J. 2005. Incidence of herpes simplex virus keratitis in France. Ophthalmology, 112: 888–895.
Lairson D R, Begley C E, Reynolds T F, Wilhelmus K R. 2003. Prevention of herpes simplex virus eye disease: a cost-effectiveness analysis. Arch Ophthalmol, 121: 108–112.
Liesegang T J. 1992. Biology and molecular aspects of herpes simplex and varicella-zoster virus infections. Ophthalmology, 99: 781–799.
Liesegang T J. 2008. Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity. Ophthalmology, 115: S3–S12.
Liesegang T J, Melton L J, 3rd, Daly P J, Ilstrup D M. 1989. Epidemiology of ocular herpes simplex. Incidence in Rochester, Minn, 1950 through 1982. Arch Ophthalmol, 107: 1155–1159.
Liu S, Pavan-Langston D, Colby K A. 2012. Pediatric herpes simplex of the anterior segment: characteristics, treatment, and outcomes. Ophthalmology, 119: 2003–2008.
Matoba A Y. 1990. Ocular disease associated with Epstein-Barr virus infection. Surv Ophthalmol, 35: 145–150.
Matsuo T, Itami M. 2002. Seropositivity of human herpesvirus-8 in patients with uveitis. Ocul Immunol Inflamm, 10: 197–199.
Mechai F, Boutolleau D, Manceron V, Gasnault J, Quertainmont Y, Brosseau J P, Delfraissy J F, Labetoulle M, and Goujard C. 2007. Human herpesvirus 6-associated retrobulbar optic neuritis in an HIV-infected patient: response to anti-herpesvirus therapy and long-term outcome. J Med Virol, 79: 931–934.
Murray P R, Rosenthal K S, Pfaller M A. 2005. Human Herpesviruses Medical microbiology, 5th ed. Philadelphia: Elsevier Mosby, pp. 461–484.
Musch D C, Martin D F, Gordon J F, Davis M D, Kuppermann B D. 1997. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group. N Engl J Med, 337: 83–90.
Newman H, Gooding C. 2013. Viral ocular manifestations: a broad overview. Rev Med Virol, 23: 281–294.
Nguyen L H, Knipe D M, Finberg R W. 1992. Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection. J Virol, 66: 7067–7072.
Nguyen Q D, Kempen J H, Bolton S G, Dunn J P, Jabs D A. 2000. Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy. Am J Ophthalmol, 129: 634–639.
Nilsen A, Myrmel H. 2000. Changing trends in genital herpes simplex virus infection in Bergen, Norway. Acta Obstet Gynecol Scand, 79: 693–696.
Ogata N, Koike N, Yoshikawa T, Takahashi K. 2011. Human herpesvirus 6-associated uveitis with optic neuritis diagnosed by multiplex PCR. Jpn J Ophthalmol, 55: 502–505.
Ohara P T, Chin M S, LaVail J H. 2000. The spread of herpes simplex virus type 1 from trigeminal neurons to the murine cornea: an immunoelectron microscopy study. J Virol, 74: 4776–4786.
Opstelten W, Zaal M J. 2005. Managing ophthalmic herpes zoster in primary care. BMJ, 331: 147–151.
Oxman M N, Levin M J, Johnson G R, Schmader K E, Straus S E, Gelb L D, Arbeit R D, Simberkoff M S, Gershon A A, Davis L E, Weinberg A, Boardman K D, Williams H M, Zhang J H, Peduzzi P N, Beisel C E, Morrison V A, Guatelli J C, Brooks P A, Kauffman C A, Pachucki C T, Neuzil K M, Betts R F, Wright P F, Griffin M R, Brunell P, Soto N E, Marques A R, Keay S K, Goodman R P, Cotton D J, Gnann J W, Jr., Loutit J, Holodniy M, Keitel W A, Crawford G E, Yeh S S, Lobo Z, Toney J F, Greenberg R N, Keller P M, Harbecke R, Hayward A R, Irwin M R, Kyriakides T C, Chan C Y, Chan I S, Wang W W, Annunziato P W, Silber J L, Shingles Prevention Study G. 2005. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med, 352: 2271–2284.
Palestine A G. 1988. Clinical aspects of cytomegalovirus retinitis. Rev Infect Dis, 10Suppl 3: S515–S521.
Papaloukas O, Giannouli G, Papaevangelou V. 2014. Successes and challenges in varicella vaccine. Ther Adv Vaccines, 2: 39–55.
Pepose J S, Keadle T L, Morrison L A. 2006. Ocular herpes simplex: changing epidemiology, emerging disease patterns, and the potential of vaccine prevention and therapy. Am J Ophthalmol, 141: 547–557.
Centers for Disease Control and Prevention. 2012. Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, Wolfe S, Hamborsky J, eds. 12th ed., second printing. Washington DC: Public Health Foundation, pp301–324.
Prober C G, Kirk L E, Keeney R E. 1982. Acyclovir therapy of chickenpox in immunosuppressed children—a collaborative study. J Pediatr, 101: 622–625.
Rabenau H F, Buxbaum S, Preiser W, Weber B, Doerr H W. 2002. Seroprevalence of herpes simplex virus types 1 and type 2 in the Frankfurt am Main area, Germany. Med Microbiol Immunol, 190: 153–160.
Revere K, Davidson S L. 2013. Update on management of herpes keratitis in children. Curr Opin Ophthalmol, 24: 343–347.
Rocha G, Muzychuk M. 2010. Herpes Zoster Ophthalmicus: More than meets the eye. Clinical & Surgical Ophthalmology, 28: 11–16.
Rowe A M, St Leger A J, Jeon S, Dhaliwal D K, Knickelbein J E, Hendricks R L. 2013. Herpes keratitis. Prog Retin Eye Res, 32: 88–101.
Roy F H, Fraunfelder F W, Fraunfelder F T. 2008. Roy and Fraunfelder’s Current Ocular Therapy. Elsevier Saunders.
Sacchetti M, Lambiase A. 2014. Diagnosis and management of neurotrophic keratitis. Clin Ophthalmol, 8: 571–579.
Schmader K, Gnann J W, Jr., Watson C P. 2008. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis, 197Suppl 2: S207–S215.
Schreiber A, Harter G, Schubert A, Bunjes D, Mertens T, Michel D. 2009. Antiviral treatment of cytomegalovirus infection and resistant strains. Expert Opin Pharmacother, 10: 191–209.
Scoular A, Norrie J, Gillespie G, Mir N, Carman W F. 2002. Longitudinal study of genital infection by herpes simplex virus type 1 in Western Scotland over 15 years. BMJ, 324: 1366–1367.
Shaikh S, Ta C N. 2002. Evaluation and management of herpes zoster ophthalmicus. Am Fam Physician, 66: 1723–1730.
Simberkoff M S, Arbeit R D, Johnson G R, Oxman M N, Boardman K D, Williams H M, Levin M J, Schmader K E, Gelb L D, Keay S, Neuzil K, Greenberg R N, Griffin M R, Davis L E, Morrison V A, Annunziato P W, Shingles Prevention Study G. 2010. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med, 152: 545–554.
Slobod K S, Sandlund J T, Spiegel P H, Haik B, Hurwitz J L, Conley M E, Bowman L C, Benaim E, Jenkins J J, Stocks R M, Gan Y, Sixbey J W. 2000. Molecular evidence of ocular Epstein-Barr virus infection. Clin Infect Dis, 31: 184–188.
Smith J S, Robinson N J. 2002. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis, 186Suppl 1: S3–S28.
Stanberry L R, Spruance S L, Cunningham A L, Bernstein D I, Mindel A, Sacks S, Tyring S, Aoki F Y, Slaoui M, Denis M, Vandepapeliere P, Dubin G, GlaxoSmithKline Herpes Vaccine Efficacy Study G. 2002. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med, 347: 1652–1661.
Stein-Streilein J. 2008. Immune regulation and the eye. Trends Immunol, 29: 548–554.
Steiner I, Kennedy P G, Pachner A R. 2007. The neurotropic herpes viruses: herpes simplex and varicella-zoster. Lancet Neurol, 6: 1015–1028.
Stewart M W. 2010. Optimal management of cytomegalovirus retinitis in patients with AIDS. Clin Ophthalmol, 4: 285–299.
Sundmacher R. 2009. Color atlas of herpetic eye disease: a practical guide to clinical management. Berlin: Springer, pp. 51–56.
Sung H, Schleiss M R. 2010. Update on the current status of cytomegalovirus vaccines. Expert Rev Vaccines, 9: 1303–1314.
Suzuki T, Ohashi Y. 2008. Corneal endotheliitis. Semin Ophthalmol, 23: 235–240.
Tappuni A R. 2011. Immune reconstitution inflammatory syndrome. Adv Dent Res, 23: 90–96.
Tasman W, Jaeger E A. 2013. Duane’s ophthalmology on DVD-ROM-2013 edition. http://80.36.73.149/almacen/medicina/oftalmologia/enciclopedias/duane/pages/v3c028a.html.
Toma H S, Murina A T, Areaux R G, Jr., Neumann D M, Bhattacharjee P S, Foster T P, Kaufman H E, Hill J M. 2008. Ocular HSV-1 latency, reactivation and recurrent disease. Semin Ophthalmol, 23: 249–273.
Tran T, Druce J D, Catton M C, Kelly H, Birch C J. 2004. Changing epidemiology of genital herpes simplex virus infection in Melbourne, Australia, between 1980 and 2003. Sex Transm Infect, 80: 277–279.
Tyring S K. 2006. Mucosal immunology and virology. Springer, London, pp.179–189.
Tyring S K. 2007. Management of herpes zoster and postherpetic neuralgia. J Am Acad Dermatol, 57: S136–S142.
Varani S, Landini M P. 2011. Cytomegalovirus-induced immunopathology and its clinical consequences. Herpesviridae, 2: 6.
Varani S, Spezzacatena P, Manfredi R, Chiodo F, Mastroianni A, Ballarini P, Boschini A, Lazzarotto T, Landini M P. 2000. The incidence of cytomegalovirus (CMV) antigenemia and CMV disease is reduced by highly active antiretroviral therapy. Eur J Epidemiol, 16: 433–437.
Weinberg A, Zhang J H, Oxman M N, Johnson G R, Hayward A R, Caulfield M J, Irwin M R, Clair J, Smith J G, Stanley H, Marchese R D, Harbecke R, Williams H M, Chan I S, Arbeit R D, Gershon A A, Schodel F, Morrison V A, Kauffman C A, Straus S E, Schmader K E, Davis L E, Levin M J, US Department of Veterans Affairs (VA) Cooperative Studies Program Shingles Prevention Study Investigators. 2009. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis, 200: 1068–1077.
Wenkel H, Rummelt V, Fleckenstein B, Naumann G O. 1998. Detection of varicella zoster virus DNA and viral antigen in human eyes after herpes zoster ophthalmicus. Ophthalmology, 105: 1323–1330.
Whitcup S M. 2000. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. JAMA, 283: 653–657.
Wilhelmus K R. 2010. Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis. Cochrane Database Syst Rev, 12: CD002898.
Wilhelmus K R, Falcon M G, Jones B R. 1981. Bilateral herpetic keratitis. Br J Ophthalmol, 65: 385–387.
Wong R W, Jumper J M, McDonald H R, Johnson R N, Fu A, Lujan B J, Cunningham E T Jr. 2013. Emerging concepts in the management of acute retinal necrosis. Br J Ophthalmol, 97: 545–552.
Xu F, Sternberg M R, Kottiri B J, McQuillan G M, Lee F K, Nahmias A J, Berman S M, Markowitz L E. 2006. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA, 296: 964–973.
Yawn B P, Wollan P C, St Sauver J L, Butterfield L C. 2013. Herpes zoster eye complications: rates and trends. Mayo Clin Proc, 88: 562–570.
Yen M, Ausayakhun S, Chen J, Ausayakhun S, Jirawison C, Heiden D, Holland G N, Margolis T P, Keenan J D. 2014. Telemedicine diagnosis of cytomegalovirus retinitis by nonophthalmologists. JAMA Ophthalmol, 132: 1052–1058.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is published with open access at Springerlink.com
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Zhu, L., Zhu, H. Ocular herpes: the pathophysiology, management and treatment of herpetic eye diseases. Virol. Sin. 29, 327–342 (2014). https://doi.org/10.1007/s12250-014-3539-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12250-014-3539-2